Arterial hypertension (HT) is one of the most frequently recorded comorbidities among patients under antiangiogenic therapy. Inhibitors of vascular endothelial growth factor and vascular endothelial growth factor receptors are most commonly involved in new onset or exacerbation of pre-existing controlled HT. From the pathophysiology point of view, data support that reduced nitric oxide release and sodium and fluid retention, microvascular rarefaction, elevated vasoconstrictor levels, and globular injury might contribute to HT. The purpose of this review was to present recent evidence regarding the incidence of HT induced by antiangiogenic agents, to analyze the pathophysiological mechanisms, and to summarize current recommendations for the management of elevated blood pressure in this field. Arterial hypertension (HT) is considered one of the most commonly seen comorbidities in patients with malignancy due to the use of chemotherapeutic agents. 1 Before the introduction of antiangiogenic medications, the prevalence of HT in oncological patients was similar to the general population. Nevertheless, increased use of these agents along with consequent prolonged survival of cancer patients contributed to the new onset or worsening of preexisting HT. 2 After initiation of treatment, the vast majority of oncological patients have an absolute increase in blood pressure (BP), with a subset development of HT that ranges from 11% to 43%. Drug-related HT might occur from initiation of antiangiogenic therapy until a year after treatment onset. 3, 4 The incidence and severity of HT are influenced by patient age, specific medications used and dosage, cancer type, history of HT, and pre-existing cardiovascular risk factors. 5, 6 Given the fact that the increased BP levels might be responsible for therapy withdrawal, HT management is crucial in order to avoid interruption of treatment. 7 Among newer cancer therapies, antiangiogenic drugs are the most frequently involved in new onset or exacerbation of pre-existing but controlled HT. In particular, inhibitors of vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) have received the most attention. [8] [9] [10] Management of HT in cancer patients treated with antiangiogenic agents resembles the Greek myth of Theseus and Minotaur; the hero had to follow Ariadne's thread in order to retrace the path and get out of the labyrinth. In this context, the complexity of HT requires a stepwise approach including close collaboration of oncologists and cardiologists, repeated BP measurements, and cardiovascular profile assessment to avoid temporary or permanent interruption of chemotherapy and to achieve optimal HT control. The purpose of this review was to present recent evidence connecting HT to antiangiogenic factors and to summarize current recommendations of HT management in this field.
Arterial hypertension (HT) is considered one of the most commonly seen comorbidities in patients with malignancy due to the use of chemotherapeutic agents. 1 Before the introduction of antiangiogenic medications, the prevalence of HT in oncological patients was similar to the general population. Nevertheless, increased use of these agents along with consequent prolonged survival of cancer patients contributed to the new onset or worsening of preexisting HT. 2 After initiation of treatment, the vast majority of oncological patients have an absolute increase in blood pressure (BP), with a subset development of HT that ranges from 11% to 43%. Drug-related HT might occur from initiation of antiangiogenic therapy until a year after treatment onset. 3, 4 The incidence and severity of HT are influenced by patient age, specific medications used and dosage, cancer type, history of HT, and pre-existing cardiovascular risk factors. 5, 6 Given the fact that the increased BP levels might be responsible for therapy withdrawal, HT management is crucial in order to avoid interruption of treatment. 7 Among newer cancer therapies, antiangiogenic drugs are the most frequently involved in new onset or exacerbation of pre-existing but controlled HT. In particular, inhibitors of vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) have received the most attention. [8] [9] [10] Management of HT in cancer patients treated with antiangiogenic agents resembles the Greek myth of Theseus and Minotaur; the hero had to follow Ariadne's thread in order to retrace the path and get out of the labyrinth. In this context, the complexity of HT requires a stepwise approach including close collaboration of oncologists and cardiologists, repeated BP measurements, and cardiovascular profile assessment to avoid temporary or permanent interruption of chemotherapy and to achieve optimal HT control. The purpose of this review was to present recent evidence connecting HT to antiangiogenic factors and to summarize current recommendations of HT management in this field.
identified as angiogenic activators such as VEGF, fibroblast growth factor, angiogenin, transforming growth factor-α, transforming growth factor-β, tumor necrosis factor-α, platelet-derived endothelial growth factor (PDGF), granulocyte colony-stimulating factor, placental growth factor, interleukin-8, hepatocyte growth factor, and epidermal growth factor. On the other hand, proteins that inhibit angiogenesis include angiostatin, endostatin, interferon, platelet factor 4, thrombospondin, prolactin 16 kD fragment, and tissue inhibitor of metalloproteinase-1, -2, and -3. 13, 14 The most important pathway of the angiogenesis process is mediated by VEGF and its tyrosine kinase receptors (VEGFR-1, -2, and -3). There are 5 different VEGF isoforms (A, B, C, D, and placenta growth factor) with VEGF-A being the most clinically relative protein-promoting angiogenesis through binding mainly to VEGFR-2 (Table 1) . 10, 15 
PATHOPHYSIOLOGY OF HT
The exact mechanism of HT induced by antiangiogenic drugs is not well understood yet. Several theories have been proposed suggesting that multiple mechanisms contribute to the development of HT. Impaired endothelial function along with microvascular rarefaction and glomerular injury might be implicated in HT secondary to antiangiogenic therapy ( Figure 1 ).
Endothelial dysfunction
VEGF exerts pleiotropic effects on endothelial cells including migration and invasion into the basement membrane and proliferation. 14 Thus, VEGF inhibition induces endothelial dysfunction leading to an imbalance between endothelium-derived relaxing factors such as nitric oxide (NO) and prostacyclin (PGI2) and endothelium-derived contractile factors such as endothelin-1 (ET-1). 16, 17 It is well established that activation of VEGFR by VEGF prompts the expression of nitric oxide synthase by endothelial cells and PGI2 resulting in vasodilation due to NO release via phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Therefore, VEGF and VEGFR inhibition and subsequent vasoconstriction might be a critical mechanism underlying treatment-induced HT. Additionally, impaired NO production promotes sodium and fluid retention and further elevations of BP. [18] [19] [20] Soluble VEGFR-1, also known as soluble Flt-1, is a variant of VEGFR lacking the transmembrane and cytoplasmic domains and is expressed by endothelial cells, monocytes, and placenta. 21, 22 Available data support that soluble Flt-1 is overexpressed in several tumors types 23, 24 and binds VEGF causing endothelial dysfunction, decreasing angiogenesis, impairing capillary repair, and increasing proteinuria. 25, 26 Moreover, elevated levels of the potent vasoconstrictor ET-1 have been detected in patients treated with the VEGFR inhibitor sunitinib. 27 According to a study, soluble Flt-1 infusion in mice augmented ET-1-mediated vasoconstriction contributing to BP elevation. 28 Apart from vasoconstriction, ET-1 activates vascular NADPH oxidase resulting in oxidative stress through enhanced reactive oxygen species production. 29, 30 
Microvascular rarefaction
It is defined as a decrease in the number of perfused capillaries in an area of tissue. Angiogenesis inhibition might result in microvascular rarefaction leading to increased vascular resistance and HT. In a small study of 18 oncological patients treated with bevacizumab, microvascular rarefaction and raised BP were observed in all individuals. 19, 20, 31 
Glomerular injury
Angiogenesis inhibition might generate renal thrombotic microangiopathy and subsequent glomerular injury, but the exact mechanisms are not clear yet. In vitro, VEGF induces the formation of fenestrations in glomerular endothelial cells that are requisite for the permeability of the glomerular filtration barrier. Thus, the inhibition of VEGF might result in the loss of the healthy fenestrated phenotype and the development of thrombotic microangiopathy and microvascular injury. 32 
ANTIANGIOGENIC AGENTS AND HT
The association of HT with antiangiogenic drugs is a matter of emerging clinical concern. After initiation of therapy, severe BP rises could lead to the permanent discontinuation of these agents. 33 Numerous studies aimed to investigate the overall incidence of HT among oncological patients receiving antiangiogenic factors (Table 2 ). Of note, in all studies, patients were either normotensives or controlled hypertensives before the initiation of treatment. The majority of trials used the Common Terminology Criteria for Adverse Events (CTCAE) to classify hypertensive events (Table 3) . According to these criteria, the term "all-grade" refers to all grades from 1 to 4, while the term "high-grade" refers solely to any grade between 3 and 4, respectively. 34
Bevacizumab
Bevacizumab is a monoclonal antibody that targets VEGF molecule. 35 There is evidence that patients treated with bevacizumab have a 3-fold higher risk of HT. 36 A retrospective study of 154 patients treated with bevacizumab showed that 35% of them experienced HT secondary to therapy after a median time of 11 weeks. 37 HT was most likely to occur in patients with pre-existing HT. Indeed, 8 in 10 individuals experienced an exacerbation of pre-existing HT.
Likewise, the increased risk of bevacizumab-induced HT was revealed in a meta-analysis that included 12,656 oncological patients. The incidence of all-grade HT in patients receiving bevacizumab was 23.6% with 7.9% of them being high-grade. The relative risk of all-grade and high-grade HT was 3.02 and 5.28, respectively, compared with controls. The risk of high-grade HT also varied among patients with different tumor type with significantly increased risk observed in patients with renal cell carcinoma (RCC), non-small cell lung cancer, pancreatic cancer, and colorectal cancer. 38 
Sunitinib
Sunitinib is a potent inhibitor of VEGFR-1 and -2, PDGF receptor-a and -b, fetal liver tyrosine kinase receptor 3 (FLT3), and c-Kit (stem-cell factor [SCF] receptor). 39 In a meta-analysis of 5,000 patients treated with sunitinib, the calculated summary incidence of all-grade HT was 21.6%, whereas the incidence of high-grade HT was 6.8%. In addition, the risk of HT varied with tumor type and dosing schedule of therapy being significantly higher in patients with RCC and continuous daily-dosing schedule. 40 Moreover, among 181 patients with metastatic RCC, 33% of them developed HT after initiating sunitinib. 41 
Sorafenib
Sorafenib is a multikinase inhibitor of VEGFR-1, -2, and -3, RET receptor tyrosine kinase, RAF kinase, and PDGF receptor-b. 42 In 2 meta-analyses, the overall incidence of sorafenib-induced high-grade HT among oncological patients was 4.3% and 6%, respectively. 43 
Axitinib
Axitinib is a highly selective inhibitor of VEGFR-1, -2, and -3. 46 In a total of 1,148 cancer patients, the overall incidence of all-grade and high-grade HT after initiating therapy was 40.1% and 13.1%, respectively. The risk was significantly higher in subjects with RCC. 47 In another study of 52 oncological patients treated with axitinib, 63.5% of them developed HT after 5-year follow-up. 48 There is evidence that the risk of HT is greater in patients treated with axitinib compared with sorafenib. Indeed, 2 studies confirmed this ascertainment. In the first one, the incidence of axitinib-induced HT was 49%, whereas the incidence of sorafenib-induced HT was 29%. 49 The other study included 723 patients that were randomly allocated to receive axitinib or sorafenib. HT was developed in 42% of subjects treated with axitinib, whereas 30% of them treated with sorafenib. 50 Abbreviations: CCC, cholangiocarcinoma; CRC, colorectal cancer; GC, gastric cancer; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HT, hypertension; NA, nonavailable; NSCLC, non-small cell lung carcinoma; PC, pancreatic cancer; RCC, renal cell carcinoma; SCLC, small cell lung cancer; TC, thyroid cancer; UC, urothelial carcinoma.
Pazopanib
Pazopanib is a multityrosine kinase inhibitor targeting VEGFR-1, -2, and -3, PDGF receptor-a and -b and c-Kit. 51 In a cohort of normotensive oncological patients treated with pazopanib, 33% of them developed HT. 52 Similarly, a more recent study revealed that 57% of individuals treated with pazopanib developed HT after the initiation of therapy. The incidence of a new onset event was 17% within a median time of 19 days. 53 
Ramucirumab
Ramucirumab is a VEGFR-2 inhibitor that blocks the binding of VEGF. 54 Among 3,851 cancer patients, the risk of all-grade and high-grade HT was greater in subjects treated with ramucirumab compared with control group (20% vs. 7% for all-grade HT; 9% vs. 3% for high-grade HT). 55 A meta-analysis also showed that the risk of ramucirumab-induced all-grade and high-grade HT was 11-38% and 6-16%, respectively, whereas the incidence in the control group was significantly lower. In addition, patients with gastric and metastatic colorectal cancer were more likely to develop HT. 56 
Regorafenib
Regorafenib inhibits VEGFR-1, -2, and -3, PDGF-b, fibroblast growth factor receptor-1, c-Kit, RET protein, and BRAF protein. 57 A meta-analysis that included 5 clinical trials revealed that the pooled incidence of all-grade and highgrade HT in patients treated with regorafenib was 44% and 13%, respectively. Moreover, the risk varied with tumor type and was higher among patients with gastrointestinal stromal tumors (56%) and RCC (49%). 58 
Aflibercept
Aflibercept is a recombinant fusion protein that blocks VEGFRs and is a more potent VEGF blocker than bevacizumab. 59 According to a meta-analysis that included 4,451 patients with metastatic colorectal cancer, the use of aflibercept was associated with a significantly increased risk of allgrade (42.4%) and high-grade (17.4%) HT. 60 
Cabozantinib
Cabozantinib is a tyrosine kinase inhibitor targeting VEGFR-2. A study that included patients with thyroid cancer revealed that the risk of all-grade and high-grade HT was greater in group of subjects treated with cabozantinib compared with control group (33% vs. 5% for all-grade HT; 8% vs. 1% for high-grade HT). 61 In a more recent trial, patients with metastatic RCC were randomly assigned 1:1 to cabozantinib or everolimus, a nonangiogenesis inhibitor. The incidence of HT was higher among individuals receiving cabozantinib (37% vs. 7% for all-grade HT; 15% vs. 3% for high-grade HT). 62 
Lenvatinib
Lenvatinib is an inhibitor of VEGFR-1, -2, and -3, fibroblast growth factor receptor-1, -2, -3, and -4, PDGF receptor-a, RET, and c-Kit. 63 The safety and efficacy of lenvatinib were evaluated in SELECT trial where the risk of HT was higher among patients received lenvatinib compared with controls (68% vs. 9% for all-grade HT; 42% vs. 2% for highgrade HT). 64, 65 
Vandetanib
Vandetanib is an agent that selectively targets VEGFR, RET protein, and epidermal growth factor receptor. In a study that included patients with locally advanced or metastatic medullary thyroid cancer, individuals treated with vandetanib were at greater risk of HT compared with controls (32% vs. 5%). 66 Therefore, available data conclude that the use of antiangiogenic agents acts as an additional risk factor contributing to the increased incidence of HT in oncological patients.
HT AS A PREDICTIVE FACTOR TO ANTIANGIOGENIC THERAPY
There is evidence suggesting that HT might be considered as a clinical marker predicting the efficacy of antiangiogenic therapy. In this context, response evaluation criteria in solid tumors (RECIST) criteria were updated the previous decade. It is a set of published rules that define when cancer patients improve (respond), stay the same (stable), or worsen (progression) during treatment. 67 In a cohort of patients with metastatic RCC on sunitinib, the development of HT was correlated with higher response to therapy. 68 These findings were consistent with another study that included individuals with the same type of cancer treated with bevacizumab. Patients that did not develop HT had greater degree of progressive disease and shorter time to disease progression. 69 Furthermore, a retrospective study that evaluated individuals with metastatic colorectal cancer treated with bevacizumab showed that 73% of patients with bevacizumab-induced HT presented response to treatment and 98% achieved disease control. Conversely, only 18% of controls presented response, and 64% of them achieved disease control. 70 However, more data are needed in order to clarify the clinical significance of such observational studies.
MANAGEMENT OF HT
National Cancer Institute (NCI) issued recommendations for the BP management among patients receiving antiangiogenic agents and set the goal of 140/90 mm Hg. 71 European Society of Cardiology (ESC) also published a position paper on cancer treatment and cardiovascular toxicity including HT. The recommended goal was <140/90 mm Hg or lower in case of overt proteinuria. 72 However, these values are not yet in accordance with the recently published guidelines for HT management in the general population that target lower than 130/80 mm Hg. 73 The primary goal in this setting is to optimize risk assessment, monitoring, and safe administration of antiangiogenic drugs. The pretreatment assessment includes repeated BP measurements along with history, physical examination, and laboratory tests to estimate the cardiovascular risk profile of each patient. Pain relief and stress management are mandatory for adequate BP evaluation. 71, 72 Once therapy has been started, BP should be monitored weekly during the first cycle and then at least every 2 or 3 weeks. After the first cycle is completed and a stable BP has been achieved, BP control might be managed with routine clinical evaluations or home BP monitoring. Initiation of antihypertensive drugs should be considered when BP is higher than 140/90 mm Hg or there is an increase in diastolic BP of at least 20 mm Hg compared with pretreatment values. Temporary interruption of antiangiogenic agents might be necessary if HT is difficult to control or patients are symptomatic because of the excess BP elevation. Once BP control is achieved, therapy can be restarted to succeed maximum cancer efficacy (Figure 2 ). 71 Early detection of HT and sufficient management of BP elevations are critical to avoid severe complications. Hence, aggressive pharmacological management is recommended. However, there are no clear data regarding the superiority of any class of antihypertensive drug for HT management in oncological patients. Although there are inconclusive data concerning the renin levels during antiangiogenic therapy, 27, 74 renin-angiotensin system (RAS) inhibitors are frequently the initial treatment of choice unless there are obvious contraindications. 71, 72, 75 A retrospective study that evaluated patients with bevacizumab-induced HT revealed that quinapril, an angiotensin-converting enzyme inhibitor (ACE-I), achieved better BP control than other antihypertensive agents. 37 Another study showed that the majority of oncological patients were successfully managed with amlodipine within 7 days. 76 Thus, calcium channel blockers might constitute an alternative choice. Nonetheless, nondihydropyridine calcium channel blockers (verapamil and diltiazem) should be avoided when sunitinib or sorafenib is used due to pharmacokinetic interactions, since they are inhibitors of CYP3A4 system that is implicated in the metabolism of both sunitinib and sorafenib. 75 Furthermore, ACE-I and beta-blockers are the preferred antihypertensive medications among patients with heart failure or at risk of heart failure or left ventricular dysfunction. Drugs that increase NO release, such as the beta1-blocker nebivolol, may be considered for BP control. Other vasodilator beta-blockers, such as carvedilol, can also be used. 72 Given the relationship between VEGF and NO, nitrates or phosphodiesterase inhibitors might be an alternative mechanistic treatment as NO donors. 75 Lifestyle modifications should be also encouraged including weight loss, if needed, aerobic exercise, diet low in total and saturated fat, salt restriction, and limitation in alcohol consumption. 75 In addition, some agents such as nonsteroidal anti-inflammatory drugs (including cyclooxygenase 2 inhibitors), adrenal steroid hormones, erythropoietin, oral contraceptive hormones, and sympathomimetics (methylphenidate) that are commonly prescribed by oncologists might also increase BP. Even though there is no evidence that HT is more frequent or more severe in patients treated with the abovementioned drugs, while on antiangiogenic therapy, elevated doses of antihypertensive drugs or more frequent BP measurements are recommended. 71, 72 To date, there are no adequate data suggesting the prophylactic use of antihypertensive drugs in normotensive patients before initiating therapy with antiangiogenic agents. A prospective clinical study that included 126 patients treated with cediranib revealed that antihypertensive prophylaxis did not result in fewer dose reductions or interruptions. However, severe HT (systolic BP >180 mm Hg or diastolic BP >110 mm Hg) occurred in only 1 patient received prophylaxis vs. 18 that did not receive prophylaxis. 77 Further studies are required in this field. 
CONCLUSIONS
The vicious circle between cancer and high BP is an evolving matter of concern considering the high prevalence of both conditions. Among newer cancer therapies, antiangiogenic agents are the most frequently involved in the development of HT implicating multiple pathophysiological mechanisms. Thus, HT management remains crucial in order to avoid treatment withdrawal. Collaboration of oncologists and cardiologists is imperative to prevent and manage HT guaranteeing best patients' outcomes.
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